Fig. 1
Characterization of PD-MSCs modified with the PRL-1 gene (PD-MSCsPRL-1, PRL-1+). a GFP and PRL-1 plasmid vector map. b Expression of GFP in PD-MSCsPRL-1 using a nonviral gene delivery system (GFP+). Scale bars: 50 μm. c mRNA and d protein expression of PRL-1 in PD-MSCsPRL-1 (mean ± SD *p < 0.05 compared with naïve; individual open circle). e Stemness markers in naïve PD-MSCs and PD-MSCsPRL-1 in cells at different passages were measured by RT-PCR. f Hematopoietic, nonhematopoietic, and HLA family surface markers in PD-MSCsPRL-1 were measured by FACS analysis. g Histopathological analysis of nontransplanted (Con) or PD-MSCsPRL-1 transplanted (Tx) into NOD/SCID mouse testes after 14 weeks by H&E staining. h Osteogenic and adipogenic differentiations of PD-MSCsPRL-1 were assessed using von Kossa and Oil Red O staining. mRNA expression of i osteogenic (OC and COL1A1) and j adipogenic-specific markers (Adipsin and PPAR-γ) in undifferentiated (−) or differentiated (+) PD-MSCsPRL-1 (mean ± SD *p < 0.05 compared with the undifferentiated groups; individual open circle). Statistic significances were determined by nonparametric Mann-Whitney U test